New drug agent knocks out multiple enzymes in cancer pathway

March 26, 2009

A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

The study appears this week in the Journal of the American Chemical Society.

The new agent belongs to a class of drugs called bisphosphonates. These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.

Drug developers have tried for years to design drugs to inhibit cell survival pathways in tumor cells, focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.

Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cancer cells.

When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of breast cancer in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.

But zoledronate quickly binds to bone, reducing its efficacy in other tissues.

"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.

Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous to the use of multi-kinase inhibitors in cancer therapy.

Andrew Wang, of Academia Sinica, Taipei, and Illinois chemist Rong Cao began by producing crystallographic structures of the target enzymes and drug candidates, allowing the researchers to identify those features that would enhance the drugs' ability to bind to the enzymes. Using this and other chemical data, Illinois chemistry department research scientist Yonghui Zhang engineered new bisphosphonate compounds that bound tightly to multiple enzyme targets, but not to bone.

One of the new compounds, called BPH-715, proved to be especially potent in cell culture and effectively inhibited tumor cell growth and invasiveness.

Tadahiko Kubo, of Hiroshima University, then found that BPH-715 also killed tumor cells in mice. And Socrates Papapoulos, of Leiden University, the Netherlands, showed that the compound had a very low chemical affinity for bone.

In humans, compounds like BPH-715 and zoledronate have an added benefit in fighting cancer: They spur the proliferation of immune cells called gamma delta T-cells, which aid in killing tumor cells.

"The new drugs are about 200 times more effective than the drugs used in recent clinical trials at killing tumor cells and in activating gamma delta T-cells to kill tumor cells," Oldfield said. "They also prevent tumor progression in mice much better than do existing bisphosphonate molecules."

University of Illinois at Urbana-Champaign

---

---

	Cancer Stem Cells in Solid Tumors (Stem Cell Biology and Regenerative Medicine) by Alison L. Allan (Editor) The “cancer stem cell” hypothesis postulates that cancer arises from a subpopulation of tumor-initiating cells or cancer stem cells (CSCs). While the idea of cancer stem cells has been around for more than a hundred years, evidence from the fields of hematology and cancer biology has now demonstrated the critical role of stem cells in hematological malignancies and suggested that these same mechanisms are also central to the initiation, progression, and treatment of solid cancers. Clinical and experimental studies have shown that CSCs exhibit many classical properties of normal stem cells, including a high self-renewal capacity and the ability to generate heterogeneous lineages; the requirement for a specific “niche”/microenvironment to grow; and an increased capacity for...
	Laryngeal granular cell tumor.(PATHOLOGY CLINIC)(Clinical report): An article from: Ear, Nose and Throat Journal by Lester D.R. Thompson (Author) This digital document is an article from Ear, Nose and Throat Journal, published by Vendome Group LLC on March 1, 2009. The length of the article is 480 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Laryngeal granular cell tumor.(PATHOLOGY CLINIC)(Clinical report) Author: Lester D.R. Thompson Publication: Ear, Nose and Throat Journal (Magazine/Journal) Date: March 1, 2009 Publisher: Vendome Group LLC Volume: 88 Issue: 3 Page: 824(2) Article Type: Clinical report Distributed by Gale, a part of Cengage...
	Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer (Recent Results in Cancer Research) by Michail Ignatiadis (Editor), Christos Sotiriou (Editor), Klaus Pantel (Editor) This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs...
	When to suspect superficial basal cell carcinoma: How to approach surveillance, treatment, and palliation (Postgraduate Medicine) by JTE Multimedia A 52-year-old man was referred for evaluation of three mildly pruritic patches on his right lateral upper arm, left shoulder, and right posterior thigh. The lesions had been present for 4 years, and although itching had decreased, they had failed to clear after treatment with fluocinonide cream. The patient had a light complexion and a long history of sun exposure. Original Publication Date: November 1998
	Cancer Cell Culture: Methods and Protocols (Methods in Molecular Biology) by Ian A. Cree (Editor) With many recent advances, cancer cell culture research is more important than ever before. This timely edition of Cancer Cell Culture: Methods and Protocols covers the basic concepts of cancer cell biology and culture while expanding upon the recent shift in cell culture methods from the generation of new cell lines to the use of primary cells. There are methods to characterize and authenticate cell lines, to isolate and develop specific types of cancer cells, and to develop new cell line models. Functional assays are provided for the evaluation of clonogenicity, cell proliferation, apoptosis, adhesion, migration, invasion, senescence, angiogenesis, and cell cycle parameters. Other methods permit the modification of cells for transfection, drug resistance, immortalization, and transfer...
	Cancer Stem Cells: Methods and Protocols (Methods in Molecular Biology) by John S. Yu (Editor) Through the revolutionary concept of cancer stem cells, cancer research has been reinvigorated to study the role of these unique cells in cancer propagation and as targets of innovative therapies. In Cancer Stem Cells: Methods and Protocols, preeminent researchers have compiled cancer stem cell research techniques and protocols to promote healthy competition, discourse, and collaboration in this vital field. The volume covers extensive topics such as identification and isolation of cancer stem cells, animal models of cancer stem cells, methylation profiling, the contribution of the niche in the regulation of cancer stem cells, immunologic targeting, and the use of normal stem cells as a treatment, among other subjects. Written in the highly successful Methods in Molecular Biology™...
	Cell Mechanics: From Single Scale-Based Models to Multiscale Modeling (Chapman & Hall/CRC Mathematical & Computational Biology) by Arnaud Chauvière (Editor), Luigi Preziosi (Editor) Ubiquitous and fundamental in cell mechanics, multiscale problems can arise in the growth of tumors, embryogenesis, tissue engineering, and more. Cell Mechanics: From Single Scale-Based Models to Multiscale Modeling brings together new insight and research on mechanical, mathematical, physical, and biological approaches for simulating the behavior of cells, specifically tumor cells. In the first part of the text, the book discusses the powerful tool of microrheology for investigating cell mechanical properties, multiphysics and multiscale approaches for studying intracellular mechanisms in cell motility, and the role of subcellular effects involving certain genes for inducing cell motility in cancer. Focusing on models based on physical, mathematical, and computational approaches, the...
	Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti-Neoplastic Biological Therapy by Bela Bodey (Author), Stuart E. Siegel (Author), Hans E. Kaiser (Author) Childhood brain tumors are a diverse group of diseases characterized by the abnormal growth of tissue contained within the skull. Other than leukemia and lymphoma, brain tumors are the most common type of neoplasms that occur in children. The leading cause of death from childhood neoplasms among persons up to 19 years is brain tumors. As such, this book is a review of the most recent molecular biological research concerning brain tumors with references and comparisons to a variety of neoplastic disorders. The book then uses this information to foreshadow the direction that future anti-neoplastic therapies will take. Because of the wide spectrum of the objectives of the book, any individual involved in cancer research will greatly benefit from the work. Histopathologists,...
	Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) by Otmar D. Wiestler (Editor), Bernhard Haendler (Editor), D. Mumberg (Editor) Cancer stem cells have originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor as they divide much more slowly and have very efficient drug resistance mechanisms. Current treatments might largely spare cancer stem cells. This book looks at recent developments in the field of cancer stem cells and the possible impact for the identification of novel treatment paradigms for cancer.
	Epidermal Cell Tumors: The Basics by Bruce R. Smoller (Author), Kim M. Hiatt (Author) Epidermal Cell Tumors: The Basics will serve as an effective and efficient handbook for the student of dermatopathology, and as a practical bench reference for the practicing diagnostician who desires rapid access to criteria that are useful in differentiating histologically similar entities. The reader will be able to focus upon a single histologic observation, i.e., inflammatory conditions without epidermal changes, and use this as a starting point from which to build a differential diagnosis based upon pattern recognition. As each entity is addressed, there will be a concise discussion of the basic clinical findings and epidemiologic associations. This will be followed by a histologic description, highlighting areas that serve to discriminate between the entity under discussion and...